Non-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in solid organ transplant (SOT) recipients and occurs at a 7–53x higher incidence vs. the general population. Additionally, the optimal management of NMSC in SOT is not well established. RP1 is an oncolytic immunotherapy (HSV-1) that expresses GM-CSF and a fusogenic glycoprotein (GALV-GP-R−).
During an oral presentation at the AACR 2024 Annual Meeting, interim findings from the ARTACUS trial of RP1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers were unveiled. As of the data, cutoff date on September 18, 2023, RP1 monotherapy, administered f...
